List of Antibodies Companies in Pennsylvania - 30

Abound Bio was acquired by Galapagos. Abound Bio is a US company whose mission is to generate novel antibody-based biological therapeutics to meet unmet medical needs in the fields of cancer and infectious disease. Galapagos acquired Abound Bio in 2022.

Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy using proprietary antibody generation platforms. The company is located in the Eastern Pennsylvania biotechnology/pharmaceutical hub 30-miles west of Philadelphia. Unique to Abzyme is our proprietary and highly engineered eukaryotic in vitro antibody discovery/optimization platform based on yeast display self-diversifying libraries, rapid target-directed antibody affinity maturation in combination with a FACS single cell sorting approach to identify desired antibodies. Abzyme’s modular antibody discovery platform incorporates a real-time screening ability to select for key properties such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity. Today, the Company has over 60 proprietary and partnered programs in development in therapeutic and diagnostic areas including infectious diseases, immuno-oncology, ophthalmology, inflammation and central nervous system disorders.

Accelerated Biosciences Corp. is commercializing human trophoblast stem cells isolated from the trophectoderm of embryos from women with ectopic pregnancies. hTSCs are ethically sourced and have immune-privileged characteristics. It is an abundant and dynamic pluripotent stem cell platform for basic research, disease modeling, toxicology, drug discovery, and cell therapy.

At Annovis Bio, Inc., we are pioneering a novel approach to fighting chronic and acute neurodegeneration, offering new hope against the largest unmet need of our aging population - Alzheimer’s and Parkinson’s diseases. Our diverse pipeline also targets such neurodegenerative conditions as traumatic brain injury (TBI), stroke, Down Syndrome, Huntington disease, and mental illnesses. Our lead compound, buntanetap, is a small, once-daily, orally administered, brain-penetrant inhibitor of neurotoxic proteins. The biological activity of buntanetap has been evaluated in 19 animal studies conducted in leading institutions such as the Karolinska Institute, Columbia University, and Harvard University. We have also conducted seven clinical studies in over 1,000 people, which consistently showed that buntanetap is safe and well-tolerated. Moreover, buntanetap has shown the ability to normalize levels of several neurotoxic proteins – APP, tau, aSYN – to those seen in healthy volunteers. In our late-stage trials, buntanetap significantly improved cognitive functions (ADAS-Cog11) in patients with mild Alzheimer’s disease, halted cognitive decline in Parkinson’s patients, and improved motor and non-motor Parkinson’s-related functions (MDS-UPDRS) in several disease subpopulations. We are currently in the process of submitting our latest data to the FDA and planning two pivotal Phase 3 studies—one for Alzheimer’s and one for Parkinson’s. We believe that buntanetap holds the potential to be the first drug to address the underlying mechanisms of neurodegeneration, heralding a new era in the treatment of these debilitating diseases.

APTAGEN Labs is a biotechnology company offering aptamer and aptabody custom-based services to replace antibodies in research, diagnostic platforms, drug discovery and therapeutics. Aptagen was formed in 2004. Operations began in 2006. Aptagen is located in Jacobus, PA, a suburb of York, beautifully surrounded by Lake Redman and conveniently situated off of Interstate 83. The facility is a forty minute drive from Johns Hopkins University and Hershey Medical Center.

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.

A small, agile CRO. The primary function of the scientists at BioAnalysis, LLC is to provide a collaborative workspace that enables productive and effective solutions to the client’s problems. The traditional CRO model works well, however, at BioAnalysis, LLC we believe that collaborative interactions, communication and robust experimental design along with gold-standard quality results are the true value-added. The scientists of BioAnalysis, LLC possess a wealth of experience in characterization of therapeutic proteins, mAbs, and ADC (DARs), non-biologics (Polymers, PEO/PLA, nanoparticles), ICH/FDA regulatory applications, process development, and assessment of final biologic product formulations. Our subject matter expertise in the areas of Biophysics and Proteomics is showcased in over 70 peer reviewed publications.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) is a biopharmaceutical company developing innovative cell therapy platforms for patients with cancer.

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, visit www.contexttherapeutics.com.

Cube Biotech is a contract research organization of membrane protein scientists offering non-GMP services for many applications. We assist in protein preparation, biophysical target characterization, and structure determination by cryo-EM or assay development. Our USP is a vast synthetic copolymer portfolio, enabling more reliable membrane protein research. Copolymers offer, in contrast to detergents, a broad and native picture of your target. Discover endless customization possibilities with our Protein Services – your project, your way, as easy as building with Lego bricks! Build frameworks that are easily incorporated into your own processes. Choose between FTE-based, fee-for-service-based, and milestone-based models. We are looking for long-term collaborations with industrial and academic partners. Contact us to learn more.

Diverse Biotech is an innovative, clinical-stage biopharmaceutical research company that is committed to discovering and developing novel therapeutics from its proprietary drug platform.

Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.

INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to save and protect lives worldwide. The company is focused on rapidly bringing to market precisely designed and delivered DNA medicines to potentially treat and protect people from serious and life-threatening diseases associated with HPV, cancer, and infectious diseases.

Integral Molecular is a research-driven biotechnology company specializing in antibodies, viruses, and membrane proteins. We develop technologies for solving big scientific challenges and advancing therapies against difficult-to-treat diseases. Our products, platforms, and services enable antibody discovery, biotherapeutic safety profiling, vaccine development, protein engineering, and more. Learn why top pharmaceutical and biotechnology companies trust Integral Molecular. Instagram: IntegralMolecular

Jackson ImmunoResearch Laboratories, Inc. specializes in the manufacture of secondary antibodies and complementary products for life science applications. Maintaining the highest standards in our research, manufacturing and operations contributes to product quality, long term product consistency and reliable performance.

LabyRx Immuno-Oncology is a bio-medical company focused on developing a comprehensive platform for treating adenocarcinomas, a class of glandular-related tumors that represent approximately 40% of worldwide cancer cases and 50% of treatment-related spending. Based upon our scientists' discovery and ongoing research into the unique adenocarcinoma target – Labyrinthin – the Company aims to advance novel cancer therapeutic technologies that improve treatment processes. The team comprise renown scientists in the United States and Hong Kong working towards cancer therapeutics and diagnostics.

"Discover the World of LAMPIRE Biological Laboratories! Are you looking for cutting-edge solutions in the life sciences industry? Look no further! LAMPIRE Biological Laboratories, established in 1977, is a leading provider of top-notch biological products and services. Specialized Offerings: LAMPIRE excels in polyclonal and monoclonal antibody development, and a wide variety of biological products. From secondary antibodies to purified IgGs, human and animal blood products, and an extensive range of animal tissues and organs, we have everything you need for your research and diagnostic needs. Comprehensive Services: Our commitment goes beyond products. Our team of experts provides a range of support services, including peptide synthesis, antigen design, antibody purification, custom conjugation, and immunoassay development. Let us accelerate your research and take it to new heights! Trusted Worldwide: At LAMPIRE, we take pride in earning primary vendor status with biopharmaceutical, diagnostic, and medical device manufacturers worldwide. Our quality and reliability have made us a preferred partner in the industry. Customer-Centric Approach: Your success is our priority. We believe in providing each customer with our best efforts at all times. Our courteous and attentive treatment is a testament to our commitment to your satisfaction. Connect with Us: Ready to explore the world of LAMPIRE Biological Laboratories? Visit our website at www.lampire.com to learn more about our products and services. You can also reach out to us via email at lampire@lampire.com or call us at 215-795-2838 with any inquiries. Join the community of researchers and scientists who trust LAMPIRE for their critical projects. Let's drive innovation together!"

Navrogen Inc. is a biopharmaceutical company focused on the targeted treatment of cancer. Navrogen is currently working on enhancing the immune system to fight cancer by removing the effect of factors produced or induced by tumor cells which inhibit the cancer-fighting humoral immune system.

Novasenta discovers novel therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer

Opsidio is a biotechnology company that develops novel biologic therapeutics for patients suffering from fibrotic and allergic diseases. They are passionate about developing remedies for the millions of people affected by the damaging effects of chronic inflammation.

OraSure Technologies developd, manufactured and distributed of point-of-care diagnostic tests, molecular collection devices. These include rapid tests for the detection of antibodies to HIV and Hepatitis C (HCV) on the OraQuick® platform; sample self-collection and stabilization products for molecular applications; and oral fluid laboratory tests for detecting various drugs of abuse. Orasure's wholly-owned subsidiaries include DNA Genotek, CoreBiome, and Novosanis.COVID-19: BARDA funded the development of a rapid coronavirus test that can be self-administered at home.

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision's CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

Reaction Biology provides scientists worldwide with a trusted research partner supporting all phases of preclinical drug discovery from target validation through hit identification, hit to lead and lead optimization. Our portfolio covers most of your needs in drug discovery – over 2,000 biochemical targets, hundreds of cell-based assays, an extensive array of in vivo oncology models, along with custom assay development and protein production. Our team of Ph.D. scientists will provide you with collaborative support, quality data, and excellent communication, for a superior research result. Our target categories include kinases, epigenetic targets, proteases, PARPs, and many more. We also offer a line of high-quality epigenetic and kinase proteins for sale. Assay platforms include radiolabeled and fluorescent biochemical assays, biophysical assays, ion channel, cell-based assays including a wide array of target engagement assays, and in vivo oncology models including our SubQperior tumor models. From our labs in the US and Germany, Reaction Biology performs research projects for customers around the globe on a fee-for-service basis and as an integrated partner, and we would be delighted to support your research needs, too. Let's discover together.

Rockland Antibodies is a biotechnology company that offers a wide range of antibodies for academic, biopharma, and diagnostic professionals, catering to various research and development needs.

Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (“SVV-001”), a best in class oncolytic virus. SVV-001 is already in Phase I/II and has a clinical safety record in humans. SVV-001 binds to the TEM8 receptor which is common in many solid tumors like breast cancer, lung cancer and neuroendocrine tumors. SVV-001 is also being considered as a viral vector for gene therapy targeting the TEM8 receptor in solid tumors.

Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.

The Northeast Biomanufacturing Center and Collaborative (NBC2) is a National Science Foundation Advanced Technology Educationregional center that has been in existence since 2005. It's mission is tocoordinate local and regional efforts into a national biomanufacturing education and training system to promote, create, and sustain a qualified workforce with a vision to be the nationally recognized center of excellence that develops a world-class sustainable biomanufacturing workforce to improve the quality of life.

Uniquity Bio is a clinical-stage drug development company dedicated to advancing scientific innovation to deliver novel medicines for patients with immunology and inflammation conditions.